{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:44:59Z","timestamp":1777574699492,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"crossref","award":["NCKUH-11306007"],"award-info":[{"award-number":["NCKUH-11306007"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["NSTC 113-2327-B-006-001"],"award-info":[{"award-number":["NSTC 113-2327-B-006-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fibrosing interstitial lung diseases (fILDs) exhibit diverse clinical courses and prognoses, with no established biomarkers for predicting acute exacerbation (AE) and early death. This study introduces a novel composite \u201cBMP index\u201d, integrating body mass index (BMI), mucin-1, and pentraxin 3 (PTX3) to assess AE and early death risk in fILDs. Between January, 2017, and May, 2025, we enrolled 366 patients with fILDs diagnosed, managed and followed at three hospitals in southern Taiwan. Using stratified randomization with a ratio 3:2, participants were assigned to derivation (218 patients) and validation (148 patients) cohorts. Baseline circulating mucin-1 and PTX3 levels were measured via enzyme-linked immunosorbent assay. One point was assigned for each of the three components of the BMP index: BMI\u2009&lt;\u200924\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , mucin-1\u2009\u2265\u20092.5 ng\/mL, and PTX3\u2009\u2265\u20092.2 ng\/mL, yielding a total score from 0 to 3. The BMP index consistently stratified risk across the derivation, validation, and combined whole cohorts, with higher scores indicating increased AE and early death risks. Sensitivity analyses and comparative performance assessments confirming its robustness and superior predictive performance compared to multiple recently reported predictors. Our findings support the BMP index as a non-spirometric, noninvasive, radiation-free tool for early clinical risk stratification in fILDs.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-32619-1","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:24:25Z","timestamp":1765715065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel, non-spirometric \u201cBMP index\u201d for predicting severe adverse outcomes in fibrosing interstitial lung diseases"],"prefix":"10.1038","volume":"16","author":[{"given":"Tang-Hsiu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Yu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-I.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Ping","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yau-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Tse","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Chang","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"issue":"10","key":"32619_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek, M. & Cottin, V. Spectrum of fibrosing lung diseases. N. Engl. J. Med. 383 (10), 958\u2013968 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"32619_CR2","doi-asserted-by":"publisher","first-page":"2004507","DOI":"10.1183\/13993003.04507-2020","volume":"58","author":"M Selman","year":"2021","unstructured":"Selman, M. & Pardo, A. When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases. Eur. Respir. J. 58 (3), 2004507 (2021).","journal-title":"Eur. Respir. J."},{"issue":"9","key":"32619_CR3","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205 (9), e18\u2013e47 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"32619_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","volume":"5","author":"TM Maher","year":"2017","unstructured":"Maher, T. M. et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir. Med. 5 (12), 946\u2013955 (2017).","journal-title":"Lancet Respir. Med."},{"issue":"19","key":"32619_CR5","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 378 (19), 1811\u20131823 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"151","key":"32619_CR6","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin, V. et al. Fibrosing interstitial lung diseases: knowns and unknowns. Eur. Respir. Rev. 28 (151), 180100 (2019).","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"32619_CR7","doi-asserted-by":"publisher","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","volume":"57","author":"M Nasser","year":"2021","unstructured":"Nasser, M. et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur. Respir. J. 57 (2), 2002718 (2021).","journal-title":"Eur. Respir. J."},{"issue":"3","key":"32619_CR8","doi-asserted-by":"publisher","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","volume":"61","author":"SK Rajan","year":"2023","unstructured":"Rajan, S. K. et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur. Respir. J. 61 (3), 2103187 (2023).","journal-title":"Eur. Respir. J."},{"issue":"150","key":"32619_CR9","doi-asserted-by":"publisher","first-page":"180071","DOI":"10.1183\/16000617.0071-2018","volume":"27","author":"M Kolb","year":"2018","unstructured":"Kolb, M. et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 27 (150), 180071 (2018).","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"32619_CR10","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1378\/chest.14-0976","volume":"147","author":"JH Chung","year":"2015","unstructured":"Chung, J. H. et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest. 147 (2), 450\u2013459 (2015).","journal-title":"Chest"},{"key":"32619_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12890-016-0245-x","volume":"16","author":"S Piciucchi","year":"2016","unstructured":"Piciucchi, S. et al. From traction bronchiectasis to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? BMC Pulm. Med. 16, 87 (2016).","journal-title":"BMC Pulm. Med."},{"key":"32619_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.nut.2018.12.008","volume":"62","author":"S Jouneau","year":"2019","unstructured":"Jouneau, S. et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition 62, 115\u2013121 (2019).","journal-title":"Nutrition"},{"issue":"5","key":"32619_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1378\/chest.06-2784","volume":"131","author":"M Alakhras","year":"2007","unstructured":"Alakhras, M., Decker, P. A., Nadrous, H. F., Collazo-Clavell, M. & Ryu, J. H. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 131 (5), 1448\u20131453 (2007).","journal-title":"Chest"},{"issue":"1","key":"32619_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","volume":"21","author":"S Jouneau","year":"2020","unstructured":"Jouneau, S. et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir. Res. 21 (1), 312 (2020).","journal-title":"Respir. Res."},{"issue":"2","key":"32619_CR15","doi-asserted-by":"publisher","first-page":"00037","DOI":"10.1183\/23120541.00037-2021","volume":"7","author":"N Awano","year":"2021","unstructured":"Awano, N. et al. Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis. ERJ Open. Res. 7 (2), 00037\u20132021 (2021).","journal-title":"ERJ Open. Res."},{"issue":"2","key":"32619_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000518855","volume":"101","author":"S Jouneau","year":"2022","unstructured":"Jouneau, S. et al. Post hoc analysis of clinical outcomes in Placebo- and Pirfenidone-Treated patients with IPF stratified by BMI and weight loss. Respiration 101 (2), 142\u2013154 (2022).","journal-title":"Respiration"},{"issue":"6","key":"32619_CR17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.clnu.2022.05.001","volume":"41","author":"S Jouneau","year":"2022","unstructured":"Jouneau, S. et al. Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clin. Nutr. 41 (6), 1335\u20131342 (2022).","journal-title":"Clin. Nutr."},{"issue":"1","key":"32619_CR18","doi-asserted-by":"publisher","first-page":"11921","DOI":"10.1038\/s41598-024-62572-4","volume":"14","author":"HY Yoon","year":"2024","unstructured":"Yoon, H. Y., Kim, H., Bae, Y. & Song, J. W. Body mass index is associated with clinical outcomes in idiopathic pulmonary fibrosis. Sci. Rep. 14 (1), 11921 (2024).","journal-title":"Sci. Rep."},{"issue":"5","key":"32619_CR19","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.chest.2021.11.008","volume":"161","author":"A Comes","year":"2022","unstructured":"Comes, A. et al. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest 161 (5), 1320\u20131329 (2022).","journal-title":"Chest"},{"issue":"1","key":"32619_CR20","doi-asserted-by":"publisher","first-page":"2311845","DOI":"10.1080\/07853890.2024.2311845","volume":"56","author":"X He","year":"2024","unstructured":"He, X. et al. Body mass index and weight loss as risk factors for poor outcomes in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Ann. Med. 56 (1), 2311845 (2024).","journal-title":"Ann. Med."},{"key":"32619_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.chest.2020.03.037","volume":"158","author":"Y Inoue","year":"2020","unstructured":"Inoue, Y. et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 158, 646\u2013659 (2020).","journal-title":"Chest"},{"issue":"12","key":"32619_CR22","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.3390\/ijms241210196","volume":"24","author":"F Drakopanagiotakis","year":"2023","unstructured":"Drakopanagiotakis, F., Markart, P. & Steiropoulos, P. Acute exacerbations of interstitial lung diseases: focus on biomarkers. Int. J. Mol. Sci. 24 (12), 10196 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"159","key":"32619_CR23","doi-asserted-by":"publisher","first-page":"200149","DOI":"10.1183\/16000617.0149-2020","volume":"30","author":"B Ballester","year":"2021","unstructured":"Ballester, B., Milara, J. & Cortijo, J. The role of mucin 1 in respiratory diseases. Eur. Respir. Rev. 30 (159), 200149 (2021).","journal-title":"Eur. Respir. Rev."},{"issue":"7","key":"32619_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/10408363.2024.2350374","volume":"61","author":"Y Gao","year":"2024","unstructured":"Gao, Y., Du, T., Yang, L. & Wu, L. Research progress of KL-6 in respiratory system diseases. Crit. Rev. Clin. Lab. Sci. 61 (7), 599\u2013615 (2024).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"11","key":"32619_CR25","doi-asserted-by":"publisher","first-page":"e1099","DOI":"10.1002\/ctm2.1099","volume":"12","author":"JY Chi","year":"2022","unstructured":"Chi, J. Y. et al. Blockade of the pentraxin 3\/CD44 interaction attenuates lung injury-induced fibrosis. Clin. Transl. Med. 12 (11), e1099 (2022).","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"32619_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12890-021-01530-6","volume":"21","author":"TH Huang","year":"2021","unstructured":"Huang, T. H. et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm. Med. 21 (1), 165 (2021).","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"32619_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3390\/biomedicines12020402","volume":"12","author":"TH Huang","year":"2024","unstructured":"Huang, T. H. et al. Baseline blood levels of Mucin-1 are associated with crucial On-Treatment adverse outcomes in patients with idiopathic pulmonary fibrosis receiving antifibrotic Pirfenidone. Biomedicines 12 (2), 402 (2024).","journal-title":"Biomedicines"},{"issue":"10","key":"32619_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley, B. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 156 (10), 684\u2013691 (2012).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"32619_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","volume":"204","author":"M Kreuter","year":"2021","unstructured":"Kreuter, M. et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 204 (1), 74\u201381 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"32619_CR30","doi-asserted-by":"publisher","first-page":"e001063","DOI":"10.1136\/bmjresp-2021-001063","volume":"8","author":"SL Barratt","year":"2021","unstructured":"Barratt, S. L. et al. Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study. BMJ Open. Respir. Res. 8 (1), e001063 (2021).","journal-title":"BMJ Open. Respir. Res."},{"key":"32619_CR31","doi-asserted-by":"publisher","first-page":"106686","DOI":"10.1016\/j.rmed.2021.106686","volume":"191","author":"N Bernardinello","year":"2022","unstructured":"Bernardinello, N. et al. The clinical relevance of lymphocyte to monocyte ratio in patients with idiopathic pulmonary fibrosis (IPF). Respir. Med. 191, 106686 (2022).","journal-title":"Respir. Med."},{"issue":"7","key":"32619_CR32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1164\/rccm.2111053","volume":"167","author":"AU Wells","year":"2003","unstructured":"Wells, A. U. et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am. J. Respir. Crit. Care Med. 167 (7), 962\u2013969 (2003).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"32619_CR33","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1038\/s41598-018-23073-3","volume":"8","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci. Rep. 8 (1), 4784 (2018).","journal-title":"Sci. Rep."},{"key":"32619_CR34","doi-asserted-by":"publisher","first-page":"955125","DOI":"10.3389\/fmed.2022.955125","volume":"9","author":"X Zhang","year":"2022","unstructured":"Zhang, X. et al. Blood monocyte counts as a prognostic biomarker and predictor in Chinese patients with idiopathic pulmonary fibrosis. Front. Med. (Lausanne). 9, 955125 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"18","key":"32619_CR35","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.3390\/jcm10184134","volume":"10","author":"A Zinellu","year":"2021","unstructured":"Zinellu, A. et al. The aggregate index of systemic inflammation (AISI): A novel prognostic biomarker in idiopathic pulmonary fibrosis. J. Clin. Med. 10 (18), 4134 (2021).","journal-title":"J. Clin. Med."},{"issue":"2","key":"32619_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/resp.14621","volume":"29","author":"T Suzuki","year":"2024","unstructured":"Suzuki, T. et al. Association of the lung immune prognostic index with the survival of patients with idiopathic interstitial pneumonias. Respirology 29 (2), 136\u2013145 (2024).","journal-title":"Respirology"},{"issue":"5","key":"32619_CR37","doi-asserted-by":"publisher","first-page":"2201634","DOI":"10.1183\/13993003.01634-2022","volume":"61","author":"M Karayama","year":"2023","unstructured":"Karayama, M. et al. A predictive model for acute exacerbation of idiopathic interstitial pneumonias. Eur. Respir. J. 61 (5), 2201634 (2023).","journal-title":"Eur. Respir. J."},{"issue":"3","key":"32619_CR38","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/crj.12631","volume":"12","author":"M Qiu","year":"2018","unstructured":"Qiu, M., Chen, Y. & Ye, Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin. Respir. J. 12 (3), 1084\u20131092 (2018).","journal-title":"Clin. Respir. J."},{"issue":"12","key":"32619_CR39","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.rmed.2012.09.001","volume":"106","author":"Y Horimasu","year":"2012","unstructured":"Horimasu, Y. et al. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir. Med. 106 (12), 1756\u20131764 (2012).","journal-title":"Respir. Med."},{"key":"32619_CR40","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3389\/fimmu.2019.00712","volume":"10","author":"A Doni","year":"2019","unstructured":"Doni, A. et al. The long pentraxin PTX3 as a link between innate Immunity, tissue Remodeling, and cancer. Front. Immunol. 10, 712 (2019).","journal-title":"Front. Immunol."},{"issue":"1","key":"32619_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s44197-025-00377-y","volume":"15","author":"TH Huang","year":"2025","unstructured":"Huang, T. H. et al. Shifting trends in the epidemiology and management of idiopathic pulmonary fibrosis in the era of evidence-based guidelines: A nationwide population study. J. Epidemiol. Glob. Health. 15 (1), 44 (2025).","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"5","key":"32619_CR42","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu, G. et al. American thoracic Society, European respiratory Society, Japanese respiratory Society, and Latin American thoracic Society. Diagnosis of idiopathic pulmonary Fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 198 (5), e44\u2013e68 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"32619_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard, H. R. et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am. J. Respir. Crit. Care Med. 194, 265\u2013275 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"32619_CR44","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert, M. et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 61 (1), 2200879 (2023).","journal-title":"Eur. Respir. J."},{"issue":"1","key":"32619_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12929-023-00991-7","volume":"31","author":"FW Chen","year":"2024","unstructured":"Chen, F. W. et al. Inactivation of pentraxin 3 suppresses M2-like macrophage activity and immunosuppression in colon cancer. J. Biomed. Sci. 31 (1), 10 (2024).","journal-title":"J. Biomed. Sci."},{"key":"32619_CR46","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan, R.O.C. https:\/\/www.hpa.gov.tw\/Pages\/List.aspx?nodeid=1757 (accessed 01 May 2025)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32619-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:04:17Z","timestamp":1769220257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32619-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32619"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32619-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Taiwan\u2019s Human Subjects Research Act. The protocol received joint approval from the Institutional Review Board of National Cheng Kung University Hospital (approval numbers B-ER-105-390; A-ER-109-321; A-ER-111-595; B-ER-113-004). All participants provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2805"}}